Risk Assessment Identifies Women at High Risk for Breast Cancer

Share this content:
Breast Cancer Surveillance Consortium risk model, combined with benign breast disease diagnoses acurrately estimated women’s risk.
Breast Cancer Surveillance Consortium risk model, combined with benign breast disease diagnoses acurrately estimated women’s risk.

Researchers have found that the Breast Cancer Surveillance Consortium (BCSC) risk model, combined with benign breast disease (BBD) diagnoses acurrately estimated women's risk for breast cancer using breast density and BBD diagnoses, according to a study published online ahead of print in the Journal of Clinical Oncology.

A total of 1,135,977 women age 35 to 74 years undergoing mammography with no history of breast cancer were included in the study. Seventeen percent of the women had a prior breast biopsy.

During a mean follow-up of 6.9 years, 17,908 women were diagnosed with invasive breast cancer. The BCSC BBD model slightly overpredicted risk (expected to observed ratio, 1.04; 95% CI, 1.03, 1.06) and had modest discriminatory accuracy.

RELATED: Multigene Testing Identifies More Mutations in Breast, Ovarian Cancer

Among women with proliferative findings, adding BBD to the model increased the proportion of women with an estimated 5-year risk of 3% or higher from 9.3% to 27.8% (P<0.001).

Results showed that greater numbers of high-risk women eligible for primary prevention after BBD diagnoses were identified using the BCSC BBD model.

Reference

  1. Tice JA, Miglioreti DL, Li C-S Breast density and benign breast disease: risk assessment to identify women at high risk of breast cancer. J Clin Oncol. 2015. [epub ahead of print]. doi: 10.1200/JCO.2015.60.8869http://jco.ascopubs.org/content/early/2015/08/11/JCO.2015.60.8869.abstract

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters